We also observed a significant reduction in lung metastases of colorectal tumours through intravenous delivery of our oncolytic virus driven T-cell based combination immunotherapy to target CEA-positive colorectal tumours, FAP-positive stromal cells and/or CTLA4-positive Treg cells in the tumour microenvironment. The gene discussed is CEACAM5; the disease is neoplasm.